64 results
8-K
EX-99.1
CRSP
CRISPR Therapeutics AG
21 Feb 24
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
, Vertex is actively engaging with state Medicaid organizations to secure immediate reimbursement and coverage for CASGEVY.
oOutside the U.S., Vertex … not support regulatory submissions; regulatory authorities may not approve exa-cel on a timely basis or at all; adequate pricing or reimbursement may
8-K
EX-99.1
d5jz54xmjl6dehz7zu
6 Nov 23
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
4:33pm
8-K
EX-10.1
7col2a2jp4
14 Oct 21
CRISPR Therapeutics Announces Transition of Chief Financial Officer
7:15am
S-3ASR
8ao5ex 9gtmnz1
29 Jul 21
Automatic shelf registration
5:17pm
S-3ASR
EX-4.2
qneu i2spc4
29 Jul 21
Automatic shelf registration
5:17pm
S-3ASR
EX-4.1
m99ks0cq843ymqsh
29 Jul 21
Automatic shelf registration
5:17pm